Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
News Jun 07, 2010
4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced the decision to advance the Phase II Hodgkin’s lymphoma (HL) SAPHIRE study with the HDAC inhibitor resminostat into the second Simon stage of patient recruitment.
This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.
4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019